David Dietz and Craig Werner.

Research led by David Dietz, PhD, left, and Craig T. Werner, PhD, has revealed important discoveries about the neurobiological mechanisms behind relapse in drug addiction.

Class of Proteins May Curb Drug-Seeking Behaviors

Published September 13, 2018 This content is archived.

story based on news release by ellen goldbaum

A preclinical study conducted by researchers in the Department of Pharmacology and Toxicology has shown for the first time that a class of proteins are important in the neurobiology of relapse or drug-seeking behaviors.

“When we reversed what cocaine does to the brain, by reversing Smurf1 levels, the animals reduced their drug-seeking behaviors. ”
Associate professor and chair of pharmacology and toxicology

Molecular Changes in Brain Focus of Study

Published online in July in Biological Psychiatry, the research reveals important new information about the molecular changes that occur in the brain when an individual takes cocaine, and how these molecules can be targeted to reduce drug-seeking behaviors during withdrawal.

“One of the greatest challenges with addiction is the persistent vulnerability to relapse,” says Craig T. Werner, PhD, first author on the paper and a postdoctoral associate in the Department of Pharmacology and Toxicology.

“We know that relapse rates have remained very stable despite many medical advancements, so the big question is, how can we better understand drug addiction so that we can reduce the risk of relapse?,” he adds. “We wanted to look at withdrawal and to see what happens in the brain that maintains these relapse behaviors.”

Werner is a researcher in the laboratory of David Dietz, PhD, senior author and chair of pharmacology and toxicology.

Proteins Changed in Diseased States

The publication focuses on a class of proteins known as E3 ubiquitin ligases, which work by tagging other proteins to be degraded.

“We are the first group to look at this class of proteins in drug addiction,” says Werner, noting that this class of proteins regulates the degradation of specific sets of other proteins in a highly selective manner.

“If you indirectly affect a protein through one of these E3 ubiquitin ligases, you can modulate a signaling pathway without targeting it directly.”

What is also exciting about these proteins, Werner says, is that they are changed in disease states.

“So the goal is to figure out how to return expression back to what they are in non-disease states, or in this case, how to return the neuroadaptations back to the non-addicted state,” he explains.

Smurf1 Maintains Vulnerability to Relapse

The targeted protein they studied is known as Smurf1, short for Smad ubiquitinylation regulatory factor 1.

Werner and his colleagues found that cocaine addiction in lab animals caused a decrease in Smurf1 and that after addiction, during the withdrawal period when the animals were deprived of cocaine, there was a reduction in Smurf1 protein.

“We think the cell uses this protein, and those that it interacts with, to maintain vulnerability to relapse,” he says.

“So we hypothesized that if we increased Smurf1, we could make the animals less vulnerable to relapse and actually reduce cocaine-seeking behavior,” Werner adds.

Neurobiological Mechanisms of Relapse Shown

When the researchers used viral gene therapy to overexpress Smurf1 in the animals after they had been exposed to cocaine, it reduced the relapsing behavior.

“When we reversed what cocaine does to the brain, by reversing Smurf1 levels, the animals reduced their drug-seeking behaviors,” Dietz explains.

The research is essential because it reveals the neurobiological mechanisms behind relapse, a process that is not well understood.

The researchers say the next step is to conduct more studies on the role of Smurf1 in addiction and other proteins in this class with the hope that such studies will provide the foundation for an effective therapeutic intervention for drug addiction.

National Institutes of Health Funds Study

The National Institutes of Health funded the research.

Co-authors from the Department of Pharmacology and Toxicology are:

  • Amy M. Gancarz, PhD; a former postdoctoral scholar; currently an assistant professor at California State University, Bakersfield
  • Pedro H. Gobira, PhD, postdoctoral associate; visiting scholar from University of São Paulo, Brazil
  • Jun-Xu Li, MD, PhD, associate professor
  • Jianfeng Liu, PhD, postdoctoral associate
  • Jennifer A. Martin, doctoral student
  • Swarup Mitra, PhD, postdoctoral associate
  • Shruthi A. Thomas, master’s student
  • Zijun Wang, PhD, former postdoctoral associate; currently a postdoctoral associate in physiology and biophysics

Other UB co-authors are:

Rachael L. Neve, PhD, director of the Gene Technology Core at Massachusetts General Hospital, is also a co-author.